stents

Superficial Femoral Artery In-Stent Restenosis with Drug Eluting Balloon: 2 Year Follow Up.

Original title:&nbsp;Drug-Eluting Balloons for the Treatment of the Superficial Femoral Artery In-Stent Restenosis. 2-Year Follow-Up.&nbsp;Reference:&nbsp;Vittorio Virga et al. J Am Coll Cardiol Intv 2014;7:411&ndash;5. Although the use of the self-expanding nitinol stent has improved angioplasty outcomes in femoropopliteal territory, restenosis remains a challenge still affecting at least 25% of the population in the first year.<a href="https://solaci.org/en/2014/07/08/superficial-femoral-artery-in-stent-restenosis-with-drug-eluting-balloon-2-year-follow-up/" title="Read more" >...</a>

SYNTAX study final monitoring at 5-years

Original title:&nbsp;Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial.&nbsp;Reference:&nbsp;Eur Heart J. 2014 May 21. pii: ehu213. (Epub ahead of print). The SYNTAX study was one of the largest randomized clinical studies comparing long-term results of angioplasty versus surgery in multivessel disease and /or<a href="https://solaci.org/en/2014/07/04/syntax-study-final-monitoring-at-5-years/" title="Read more" >...</a>

3 to 6 months of dual antiplatelet after DES reduced bleeding and did not raise mortality or infarction.

Original title:&nbsp;Meta-analysis of randomized clinical trials comparing short term -vs- long term dual antiplatelet therapy following drug eluting stents.&nbsp;Reference:&nbsp;El-Hayek G et al. Am J Cardiol. 2014; Epub ahead of print. This meta-analysis examined the data of four randomized and controlled studies (EXCELLENT, PRODIGY, RESET y OPTIMIZE) including 8157 patients receiving sirolimus, paclitaxel, everolimus or zotarolimus<a href="https://solaci.org/en/2014/06/24/3-to-6-months-of-dual-antiplatelet-after-des-reduced-bleeding-and-did-not-raise-mortality-or-infarction/" title="Read more" >...</a>

1-Year Clinical Outcomes of Everolimus-Eluting Bioresorbable Vascular Scaffolds in Diabetic Patients

Original title:&nbsp;1-Year Clinical Outcomes of Diabetic Patients Treated With Everolimus-Eluting Bioresorbable Vascular Scaffolds A Pooled Analysis of the ABSORB and the SPIRIT Trials.&nbsp;Reference:&nbsp;Muramatsu T et al. JACC CardiovascInterv. 2014 May;7(5):482-93. This study included ABSORB, ABSORB Extend and SPIRIT patients. A total of 136 diabetic patients and 415 non diabetic receiving everolimus-eluting bioresorbable scaffolds (Absorb) and<a href="https://solaci.org/en/2014/06/10/1-year-clinical-outcomes-of-everolimus-eluting-bioresorbable-vascular-scaffolds-in-diabetic-patients/" title="Read more" >...</a>

Orbital Atherectomy improves calcified lesions treatment outcomes

Original title:&nbsp;Pivotal Trial to Evaluate the Safety and Efficacy of the Orbital Atherectomy System in Treating de Novo, Severely Calcified Coronary Lesions (ORBIT II)&nbsp;Reference:&nbsp;Jeffrey Chambers, et al. JACC Intervention 2014;7:510-8 Severely calcified coronary lesions, traditionally associated to difficult or impossible stent implantation, asymmetric stent expansion, higher post procedural events rate, more restenosis, more lesion revascularization,<a href="https://solaci.org/en/2014/06/02/orbital-atherectomy-improves-calcified-lesions-treatment-outcomes/" title="Read more" >...</a>

Higher percentage of strut coverage in biodegradable polymer DES vs. durable polymer DES. Strut level OCT analyses

Original title:&nbsp;Randomized comparison of strut coverage between Nobori biolimus-eluting and sirolimus-eluting stents: an optical coherence tomography analysis.&nbsp;Reference: &nbsp;EuroIntervention 2014; 9-online publish-ahead-of-print February 2014 &nbsp; The aim of this study was to compare strut coverage at six months follow up after Nobori biolimus eluting stent (N- BES) implantation versus Cypher Select sirolimus eluting stent (SES) implantation.<a href="https://solaci.org/en/2014/05/27/higher-percentage-of-strut-coverage-in-biodegradable-polymer-des-vs-durable-polymer-des-strut-level-oct-analyses/" title="Read more" >...</a>

Dedicated two everolimus eluting stent strategies improve bifurcation PCI outcomes

Original title:&nbsp;Dedicated two-stents technique in complex bifurcation percutaneous coronary intervention with use of everolimus-eluting stents: The EES-bifurction study.&nbsp;Reference:&nbsp;Nisharamed I. Kherada, et al. International Journal of Cardiology 2014;174:13-17 &nbsp; Bifurcation PCI, especially 1.1.1 Medina bifurcation lesions PCI, is particularly challenging and has been associated with increased restenosis. The use of drug eluting stents (DES) associated to<a href="https://solaci.org/en/2014/05/27/dedicated-two-everolimus-eluting-stent-strategies-improve-bifurcation-pci-outcomes/" title="Read more" >...</a>

Angioplasty versus surgery in patients with critical lower limb ischemia

Original title:&nbsp;Comparative effectiveness of endovascular andsurgical revascularization for patients with peripheralartery disease and critical limb ischemia: Systematicreview of revascularization in critical limb ischemia.&nbsp;Reference:&nbsp;W Schuyler Jones, et al. (Am Heart J 2014; 167:167:489-498.e7) Lower limbs critical ischemia is the most severe condition of PAD. The morbidity, mortality and costs related thereto are well documented; however, the<a href="https://solaci.org/en/2014/05/14/angioplasty-versus-surgery-in-patients-with-critical-lower-limb-ischemia/" title="Read more" >...</a>

Increased security with bivalirudin than with heparin alone in patients without ST segment.

Original title:&nbsp;Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes or stable ischemic heart disease: results from the Evaluation of Drug-Eluting Stents and Ischemic Events registry.&nbsp;Reference:&nbsp;Bangalore S et al. CircCardiovascInterv. 2014;Epub ahead of print. Bivalirudin compared to unfractionated heparin as monotherapy is associated with a lower risk of<a href="https://solaci.org/en/2014/05/14/increased-security-with-bivalirudin-than-with-heparin-alone-in-patients-without-st-segment/" title="Read more" >...</a>

Angioplasty in sirolimus &#8211; eluting stent restenosis is safe and effective beyond the change of drug.

Original title:&nbsp;Sirolimius-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stents restenosis: Results from the ISAR-DESIRE 2 trial.&nbsp;Reference:&nbsp;Sebastian Kufner, et al. Cardiovascular Revascularization Medicine 2014, 15:69-75. &nbsp; DES restenosis has always generated a challenge and a puzzle when defining the strategy of revascularization by angioplasty: A quite used concept was to switch to<a href="https://solaci.org/en/2014/05/06/angioplasty-in-sirolimus-eluting-stent-restenosis-is-safe-and-effective-beyond-the-change-of-drug/" title="Read more" >...</a>

Top